Mandate

VINGE ADVISED THE UNDERWRITERS IN RELATION TO NORDAX’S LISTING ON NASDAQ STOCKHOLM

June 22, 2015

Vinge advised Morgan Stanley & Co International plc, Carnegie Investment Bank AB (publ), Citigroup Global Markets Ltd and ABG Sundal Collier AB in relation to Nordax listing on Nasdaq Stockholm. Nordax’s principal shareholder is Vision Capital. A prospectus was published on 4 June 2015 and the first day of trading on Nasdaq Stockholm was on 17 June 2015. The price in the offering was set at SEK 45. The total value of the offering amounts to SEK 2.847 billion, assuming that the over-allotment option is exercised in full.

Nordax is a leading niche bank in the Nordic region providing unsecured consumer loans and deposit accounts to about 95,000 customers in Sweden, Norway, Finland, Denmark and Germany. As of 31 March 2015 lending to the general public amounted to SEK 10.3 billion and deposits amounted to SEK 6.5 billion.

Vinge’s team consisted mainly of responsible partner Charlotte Levin and associates Joakim Hagberg, Sabina Börjesson and Joel Wahlberg, and Axel Hedberg regarding regulatory questions.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026